Drug discovery and development company focused on cancer and fibrosis, Redx Pharma (AIM: REDX ), announced that it has appointed Dr Jane Robertson as Chief Medical Officer. 

Following a handover, the Company also announced that Dr Andrew Saunders will leave Redx after 3 years as Chief Medical Officer in order to pursue other opportunities.   

Redx said Jane, who will commence her role at Redx on 1 March 2021, will move from her position as Chief Medical Officer at Achilles Therapeutics Ltd, a biotech company focused on the creation of a personalized T cell therapy directed against clonal tumour neoantigens. 

She has over 17 years' experience of clinical development in oncology and has ‘a breadth of experience investigating multiple tumours and agents’ including VEGF inhibitors, anti-hormonals, PARP inhibitors, nucleotide analogs and most recently cell therapies.  

Jane has also served as the Chief Medical Officer at Nucana Biomed and Kesios Therapeutics and previously held a number of senior R&D leadership roles at AstraZeneca Oncology, even leading the development of the first in class PARP inhibitor, olaparib.  

Shares in Redx Pharma have increased nearly 20% in the past month to open 3.56% lower this morning at 65.1p following the announcement. 

Jane originally trained in general medicine and haematology, working in clinical practice and translational research settings, and sub-specialising in haemato-oncology. 

"We are absolutely delighted that Jane has chosen to join our team at this exciting stage in Redx's development.  As our Chief Medical Officer, her extensive and varied experience in big pharma, biotech and clinical practice, will be invaluable as we further progress our pipeline into clinical development,” said Lisa Anson, Chief Executive of Redx Pharma. 

Commenting on her incoming role as Chief Medical Officer, Jane Robertson said: 

"I have been very impressed by Redx and its outstanding scientific team and am really looking forward to the opportunity to progress the Company's promising pipeline into differentiated clinical stage programmes in the treatment of fibrotic diseases and cancer.  

She added, “With data expected from Redx's Phase 1 RXC004 study in H1 2021, this feels like a particularly exciting time to be joining the Company." 

For more news and updates on Redx: